At a glance
ClinicalIndex Comparison RecordN/ACompleted· 82 enrolled
Drug / intervention
RestoreX +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Penile Length Maintenance Post-Prostatectomy
In Brief
A clinical study evaluating RestoreX and No treatment for Prostate Cancer and Penile Diseases. Completed, enrolled 82 participants across 1 site.
Detailed Summary
The objective of the current study is to evaluate the efficacy of a novel, class I (ie. lowest risk, clinical studies not required) medical penile traction device in preventing loss of penile length in men undergoing robotic-assisted prostatectomy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer, Penile Diseases
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
Enrollment StartMar 2018
First PostedApr 2018
Primary CompletionDec 2020
TodayJul 2026
First PostedApr 18, 2018
Enrollment StartMar 23, 2018
Primary CompletionDec 28, 2020
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 8.2 years ago
Interventions
RestoreXdevice
PTT - Penile traction therapy in the straight position.
No treatmentother
Control group. No treatment will be given for the 6 months post-prostatectomy